Xingguang Cai

Title: Innovations of Xingguang Cai in Peptide Research

Introduction

Xingguang Cai is a notable inventor based in Nanjing, China. He has made significant contributions to the field of peptide research, particularly in the development of hybrid peptides that have potential applications in pharmacology and weight management.

Latest Patents

Cai holds a patent for a "Long-acting oxyntomodulin hybrid peptide, preparation method therefor, and application thereof." This invention discloses a polypeptide that modifies oxyntomodulin (OXM) by hybridizing it with a peptide sequence of Exenatide. The innovation enables the polypeptide to resist degradation by the DPP-4 enzyme through amino acid modifications. Additionally, fatty acid chains are conjugated to enhance the pharmacologic action time and weight loss effects. The synthesis of this target polypeptide is achieved through an orthogonal protection strategy solid-phase synthesis method, resulting in a purified and freeze-dried OXM hybrid peptide.

Career Highlights

Cai is affiliated with China Pharmaceutical University, where he continues to advance his research in peptide synthesis and applications. His work has garnered attention for its potential impact on therapeutic strategies for obesity and metabolic disorders.

Collaborations

Cai collaborates with notable colleagues, including Wenlong Huang and Hai Qian, who contribute to his research endeavors and enhance the scope of his innovations.

Conclusion

Xingguang Cai's work in developing long-acting oxyntomodulin hybrid peptides represents a significant advancement in peptide research. His innovative approach has the potential to lead to effective treatments for weight management and related health issues.